Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIRGINIA G KAKLAMANI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1841235439
CMS profile
129081
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$155,979.62

125 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $41,257.57 31
Celgene Corporation $34,318.40 21
PFIZER INC. $32,947.94 19
Puma Biotechnology, Inc. $26,209.13 26
Genentech USA, Inc. $7,457.57 4
PFIZER INTERNATIONAL LLC $5,139.52 5
Sirtex Medical Inc $3,348.36 3
EISAI INC. $2,542.01 3
F. Hoffmann-La Roche AG $1,854.96 2
AstraZeneca Pharmaceuticals LP $852.77 8
Lilly USA, LLC $32.25 2
Amgen Inc. $19.14 1

Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIRGINIA G KAKLAMANI

NPI 1841235439 · CMS profile ID 129081

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIRGINIA G KAKLAMANI, NPI 1841235439, CMS profile ID 129081. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). VIRGINIA G KAKLAMANI, NPI 1841235439, CMS profile ID 129081. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
VIRGINIA G KAKLAMANI, NPI 1841235439, CMS profile ID 129081, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

125 matching records · $155,979.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 125 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–125 of 125.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $14.5803/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658212301 CMS
Puma Biotechnology, Inc. $4,500.0003/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020995 CMS
Celgene Corporation $347.6303/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672758219 CMS
Puma Biotechnology, Inc. $65.0003/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020959 CMS
Puma Biotechnology, Inc. $271.1603/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020961 CMS
EISAI INC. $2,500.0002/26/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697046077 CMS
Celgene Corporation $502.7402/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672736117 CMS
Celgene Corporation $61.6602/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672781275 CMS
Puma Biotechnology, Inc. $164.5502/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020955 CMS
Puma Biotechnology, Inc. $164.5502/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020957 CMS
Puma Biotechnology, Inc. $108.2302/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020953 CMS
Puma Biotechnology, Inc. $4,500.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020951 CMS
Novartis Pharmaceuticals Corporation $1,160.0002/06/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659720415 CMS
Celgene Corporation $132.2802/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672718821 CMS
Celgene Corporation $7,450.0002/02/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672719453 CMS
Celgene Corporation $293.8002/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672719623 CMS
Celgene Corporation $206.3002/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672997851 CMS
Celgene Corporation $176.9802/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672736400 CMS
Puma Biotechnology, Inc. $278.6001/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020963 CMS
Puma Biotechnology, Inc. $55.0001/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706020965 CMS
Novartis Pharmaceuticals Corporation $245.9201/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659720417 CMS
Novartis Pharmaceuticals Corporation $3,480.0001/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659720419 CMS
Novartis Pharmaceuticals Corporation $49.4801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659720421 CMS
PFIZER INTERNATIONAL LLC $3,750.0001/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672215713 CMS
PFIZER INTERNATIONAL LLC $1,063.0001/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672989087 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $155,979.62 125
PY2020 $103,066.07 67
PY2021 $140,670.39 93
PY2022 $114,557.45 76
PY2023 $86,074.93 57
PY2024 $97,172.70 68
PY2025 $89,928.66 70

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $222.80 1
PY2025 Principal investigator $686,601.57 69
PY2024 Recipient $3,448.00 1
PY2024 Principal investigator $395,361.60 42
PY2023 Recipient $724.26 1
PY2023 Principal investigator $453,549.50 56
PY2022 Recipient $2,422.00 2
PY2022 Principal investigator $222,988.94 33
PY2021 Recipient $1,794.03 7
PY2021 Principal investigator $898,860.32 79
PY2020 Principal investigator $1,138,811.01 103
PY2019 Principal investigator $886,149.35 212

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,872.00 12/31/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670992
Principal investigator 1 Merck Sharp & Dohme LLC $899.94 12/31/2025 Non-covered Recipient Entity
Mays Cancer Center
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors No dispute reported 06/30/2026 1232930073
Principal investigator 1 Daiichi Sankyo Inc. $407.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386780
Principal investigator 1 Daiichi Sankyo Inc. $407.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386782
Principal investigator 1 Daiichi Sankyo Inc. $421.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386784
Principal investigator 1 Daiichi Sankyo Inc. $78.60 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386786
Principal investigator 1 Daiichi Sankyo Inc. $407.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386788
Principal investigator 1 Daiichi Sankyo Inc. $407.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386790
Principal investigator 1 Daiichi Sankyo Inc. $407.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386792
Principal investigator 1 Daiichi Sankyo Inc. $421.00 12/12/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386796
Principal investigator 1 Genentech, Inc. $2,653.20 12/03/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670989
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 11/03/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386794
Principal investigator 1 Genentech, Inc. $3,976.00 10/30/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670981
Principal investigator 1 Genentech, Inc. $1,500.00 10/28/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670978
Principal investigator 1 Genentech, Inc. $1,326.60 10/28/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670985
Principal investigator 1 Genentech, Inc. $1,736.00 10/27/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679321
Principal investigator 1 Genentech, Inc. $3,472.00 10/17/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679319
Principal investigator 1 Genentech, Inc. $701.00 10/16/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679317
Principal investigator 1 BioNTech SE $1,000.00 10/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
BNT327 No dispute reported 06/30/2026 1249017400
Principal investigator 1 BioNTech SE $1,800.00 10/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
BNT327 No dispute reported 06/30/2026 1249017402
Principal investigator 1 BioNTech SE $500.00 10/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
BNT327 No dispute reported 06/30/2026 1249017404
Principal investigator 1 Stemline Therapeutics Inc. $9,000.00 10/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136161
Principal investigator 1 Genentech, Inc. $5,306.40 10/02/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670974
Principal investigator 1 Genentech, Inc. $2,500.00 09/24/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679313
Principal investigator 1 Genentech, Inc. $840.00 09/24/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679315
Principal investigator 1 Genentech, Inc. $2,280.00 09/08/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679311
Principal investigator 1 Stemline Therapeutics Inc. $70.00 09/01/2025 Non-covered Recipient Entity
UT HEALTH SAN ANTONIO MAYS CANCER CENTER
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136793
Principal investigator 1 Genentech, Inc. $6,958.00 08/25/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670966
Principal investigator 1 Genentech, Inc. $935.00 08/01/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679305
Principal investigator 1 Genentech, Inc. $4,690.00 07/29/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679303
Principal investigator 1 Genentech, Inc. $9,286.20 07/22/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670970
Principal investigator 1 Genentech, Inc. $14,070.00 07/10/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679309
Recipient Novartis Pharmaceuticals Corporation $222.80 07/09/2025 Covered Recipient Physician CLEE011A2301,CLEE011E2301,CLEE011F2301 No dispute reported 06/30/2026 1190291961
Principal investigator 1 Genentech, Inc. $5,208.00 07/03/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679307
Principal investigator 1 Genentech, Inc. $1,120.00 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679293
Principal investigator 1 Stemline Therapeutics Inc. $2,500.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136129
Principal investigator 1 Stemline Therapeutics Inc. $26,000.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136135
Principal investigator 1 Stemline Therapeutics Inc. $750.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136139
Principal investigator 1 Stemline Therapeutics Inc. $2,500.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136144
Principal investigator 1 Stemline Therapeutics Inc. $4,000.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136148
Principal investigator 1 Stemline Therapeutics Inc. $250.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136152
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 06/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136157
Principal investigator 1 Daiichi Sankyo Inc. $401.00 06/24/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386798
Principal investigator 1 Daiichi Sankyo Inc. $2,718.00 06/24/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386800
Principal investigator 1 Daiichi Sankyo Inc. $421.00 06/24/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386802
Principal investigator 1 Daiichi Sankyo Inc. $407.00 06/24/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386804
Principal investigator 1 Daiichi Sankyo Inc. $407.00 06/24/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386806
Principal investigator 1 Daiichi Sankyo Inc. $407.00 06/24/2025 Non-covered Recipient Entity
University Of Texas Health Science Center At San Antonio
DS8201-A-U302 No dispute reported 06/30/2026 1223386808
Principal investigator 1 Genentech, Inc. $24,960.00 06/05/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679289
Principal investigator 1 Stemline Therapeutics Inc. $143.64 05/23/2025 Non-covered Recipient Entity
UT HEALTH SAN ANTONIO MAYS CANCER CENTER
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136789
Principal investigator 1 Genentech, Inc. $18,760.00 05/21/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679291
Principal investigator 1 Stemline Therapeutics Inc. $94.69 05/12/2025 Non-covered Recipient Entity
UT HEALTH SAN ANTONIO MAYS CANCER CENTER
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer No dispute reported 06/30/2026 1244136786
Principal investigator 1 Genentech, Inc. $1,857.00 04/21/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670958
Principal investigator 1 Genentech, Inc. $5,688.00 04/16/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679301
Principal investigator 1 Genentech, Inc. $30,299.00 04/09/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679297
Principal investigator 1 Genentech, Inc. $3,979.80 04/04/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670962
Principal investigator 1 Genentech, Inc. $3,095.00 03/25/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670954
Principal investigator 1 Genentech, Inc. $5,773.00 03/20/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679299
Principal investigator 1 Merck Sharp & Dohme LLC $35,500.00 03/17/2025 Non-covered Recipient Entity
Mays Cancer Center
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232934766
Principal investigator 1 Eli Lilly and Company $60.05 03/10/2025 Non-covered Recipient Entity
UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO
POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1187892054
Principal investigator 1 Novartis Pharmaceuticals Corporation $750.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in No dispute reported 06/30/2026 1190307423
Principal investigator 1 Eisai Inc. $42,524.56 02/26/2025 Non-covered Recipient Entity
University Of Texas Health Science
Phase II trial of eribulin and lenvatinib in advanced solid tumors No dispute reported 06/30/2026 1244561983
Principal investigator 1 Genentech, Inc. $912.00 02/20/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211679295
Principal investigator 1 BioNTech SE $4,500.00 02/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
BNT327-02 No dispute reported 06/30/2026 1249017338
Principal investigator 1 BioNTech SE $4,000.00 02/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
BNT327-02 No dispute reported 06/30/2026 1249017340
Principal investigator 1 BioNTech SE $20,000.00 02/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
BNT327-02 No dispute reported 06/30/2026 1249017342
Principal investigator 1 Genentech, Inc. $6,633.00 01/17/2025 Non-covered Recipient Entity
The University of Texas Health Science Center at San Antonio
An open label multicenter extension study No dispute reported 06/30/2026 1211670950
Principal investigator 1 Eli Lilly and Company $25,693.00 01/13/2025 Non-covered Recipient Entity
UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO
POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1187891652
Principal investigator 1 Eli Lilly and Company $3,289.89 01/09/2025 Non-covered Recipient Entity
UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891834
Principal investigator 1 Eli Lilly and Company $317,172.00 01/06/2025 Non-covered Recipient Entity
UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187892050